butorphanol vs nalbuphine
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of butorphanol and nalbuphine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Stadol
Nubain
Butorphanol nasal spray is a strong pain medicine. It is used when other pain medicines are not strong enough or cannot be tolerated.
Nalbuphine injection is a strong pain medicine. It is used when other pain treatments don't work well enough.
This medicine treats severe pain that requires an opioid pain reliever. It is for use when other pain treatments are not strong enough or cannot be tolerated. Do not use this medicine for a long time unless your pain is still severe and other treatments are still not adequate.
Nalbuphine injection is used to manage severe pain that requires a strong opioid medicine. It can also be used before and after surgery to help with pain. It can also be used during labor and delivery for pain relief.
Butorphanol is an opioid agonist-antagonist. It works by changing how your brain and nervous system respond to pain. It attaches to certain receptors in the brain to reduce pain signals.
Nalbuphine works by attaching to opioid receptors in the brain and spinal cord. These receptors help to block pain signals. Nalbuphine both activates and blocks opioid receptors.
- • Sleepiness
- • Dizziness
- • Nausea
- • Vomiting
- • Nasal congestion
- • Feeling sleepy
- • Sweaty or clammy skin
- • Nausea
- • Vomiting
- • Dizziness
- Drug Hypersensitivity 48
- Nausea 25
- Headache 16
- Pain 16
- Pruritus 16
- Drug Hypersensitivity 36
- Foetal Exposure During Pregnancy 10
- Neonatal Asphyxia 10
- Neonatal Epileptic Seizure 10
- Pain 7
This medicine has serious warnings. It can cause addiction, abuse, and misuse, which can lead to overdose and death. It can also cause life-threatening breathing problems, especially when you first start using it or after a dose increase. Accidental use, even one dose, can cause a fatal overdose, especially in children. Using this medicine with benzodiazepines or other drugs that can make you sleepy, including alcohol, can cause serious problems, including coma and death. If you use this medicine for a long time during pregnancy, it can cause withdrawal symptoms in the newborn that could be life-threatening if not treated.
Nalbuphine can cause serious breathing problems that can be life-threatening, especially when you first start taking it or after a dose increase. Taking nalbuphine with benzodiazepines (like anxiety or sleep medicines) or other drugs that can make you sleepy, including alcohol, can cause very serious sleepiness, breathing problems, coma, and death.
If you need to use this medicine for a long time during pregnancy, it can cause withdrawal symptoms in your newborn. Make sure a newborn specialist is available when you deliver your baby.
Using nalbuphine during pregnancy may cause breathing problems in the newborn. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if nalbuphine passes into breast milk. Talk to your doctor about the risks and benefits of breastfeeding.
How to Read This butorphanol vs nalbuphine Comparison
butorphanol is classified in the Opioid Agonist-Antagonist drug class, while nalbuphine sits within the Opioid Agonist-Antagonist class. Because both drugs share the same classification, they are often considered interchangeable in theory, but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, butorphanol has 121 submissions while nalbuphine has 73. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for butorphanol or nalbuphine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.